Tuesday, July 23, 2024

This Blog Will Show You About The New Advanced Innovation In Thailand

Thailand, the special night location for the...

Who Called Me 02045996873?

Presentation: In a world loaded up with computerized...

WhatsApp Number 0131 561 4532: Unmasking the Mystery

The conundrum of WhatsApp number 0131 561...

This biotech name is one of Jim Cramer’s favorite stocks

HealthThis biotech name is one of Jim Cramer's favorite stocks


Cramer’s Stop Trading: Regeneron

Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company’s macular degeneration treatment.

If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free.

CNBC’s Jim Cramer said on “Squawk on the Street” that Regeneron is one of his favorite health-care names, describing Eylea as “a remarkable drug for macular degeneration.” The “Mad Money” host thinks the company’s stock will continue to go up, citing CEO Leonard Schleifer’s track record in management.

“I think being up [11 points] is not enough,” Jim said as shares traded $11 higher. “I think it’s going to be worth more.”

  • The CNBC Investing Club with Jim Cramer doesn’t own Regeneron. But the Club does own health-care stocks, including Eli Lilly (LLY), which has been soaring to record high after record high. Cramer’s case for Lilly centers on its new diabetes drug, which is expected to get regulatory approval to also treat obesity. Lilly also has an Alzheimer’s drug in FDA review.

Here’s a full list of the stocks in Jim’s Charitable Trust, the portfolio used by the CNBC Investing Club.


Source link

See also  Bill Ackman amplifies RFK Jr on Covid vaccines

Check out our other content

Check out other tags:

Most Popular Articles